See more : CEMEX, S.A.B. de C.V. (CXMSF) Income Statement Analysis – Financial Results
Complete financial analysis of Arcutis Biotherapeutics, Inc. (ARQT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcutis Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hunan Goke Microelectronics Co.,Ltd. (300672.SZ) Income Statement Analysis – Financial Results
- AfterMaster, Inc. (AFTM) Income Statement Analysis – Financial Results
- Podium Minerals Limited (POD.AX) Income Statement Analysis – Financial Results
- BRAVADA International Ltd (BRAV) Income Statement Analysis – Financial Results
- Goldlion Holdings Limited (0533.HK) Income Statement Analysis – Financial Results
Arcutis Biotherapeutics, Inc. (ARQT)
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 59.61M | 3.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.99M | 754.00K | 763.00K | 455.00K | 195.00K | 0.00 | 0.00 |
| Gross Profit | 54.62M | 2.93M | -763.00K | -455.00K | -195.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 91.63% | 79.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 110.58M | 182.44M | 145.56M | 115.31M | 36.52M | 17.94M | 3.41M |
| General & Administrative | 0.00 | 122.12M | 60.97M | 21.34M | 6.61M | 1.80M | 695.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 185.15M | 122.12M | 60.97M | 21.34M | 6.61M | 1.80M | 695.00K |
| Other Expenses | 0.00 | 5.82M | 173.00K | 967.00K | 1.14M | 480.00K | -872.00K |
| Operating Expenses | 295.72M | 304.56M | 206.53M | 136.65M | 43.13M | 19.74M | 4.11M |
| Cost & Expenses | 300.71M | 305.31M | 206.53M | 136.65M | 43.13M | 19.74M | 4.11M |
| Interest Income | 0.00 | 9.83M | 173.00K | 967.00K | 1.14M | 0.00 | 0.00 |
| Interest Expense | 29.71M | 15.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88M | 1.25M | 763.00K | 455.00K | 195.00K | 19.74M | 4.11M |
| EBITDA | -227.43M | -294.55M | -205.59M | -135.22M | -41.80M | 480.00K | -872.00K |
| EBITDA Ratio | -381.56% | -8,025.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -241.10M | -301.63M | -206.53M | -136.65M | -43.13M | -19.74M | -4.11M |
| Operating Income Ratio | -404.49% | -8,183.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -17.93M | -9.83M | 173.00K | 967.00K | 1.14M | 480.00K | -872.00K |
| Income Before Tax | -259.03M | -311.46M | -206.36M | -135.68M | -42.00M | -19.26M | -4.98M |
| Income Before Tax Ratio | -434.57% | -8,449.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.11M | 9.83M | -454.00K | -84.30K | 23.14K | -480.00K | -4.11M |
| Net Income | -262.14M | -321.29M | -205.90M | -135.68M | -42.00M | -19.26M | -4.98M |
| Net Income Ratio | -439.79% | -8,716.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.78 | -5.84 | -4.17 | -3.80 | -1.10 | -0.53 | -0.14 |
| EPS Diluted | -3.78 | -5.84 | -4.17 | -3.80 | -1.10 | -0.53 | -0.14 |
| Weighted Avg Shares Out | 69.31M | 55.03M | 49.41M | 35.67M | 38.09M | 36.24M | 36.24M |
| Weighted Avg Shares Out (Dil) | 69.31M | 55.03M | 49.41M | 35.67M | 38.09M | 36.24M | 36.24M |
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?
Arcutis Biotherapeutics, Inc. (ARQT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARQT's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden...
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?
The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 60.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors
After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average
From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now
Arcutis Biotherapeutics (ARQT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near...
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
Arcutis Biotherapeutics, Inc. (ARQT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARQT broke through the 20-day moving average, which suggests a short-term bullish trend.
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Following the successful product launch of Zoryve, Arcutis Biotherapeutics has returned an impressive +200% year-to-date. Recent Q3 earnings impressed, with a blistering 452% year-over-year and 45% quarter-over-quarter revenue growth. The growth trend seems poised to continue, with an expanding total...
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
The consensus price target hints at a 70.3% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Investor Relations Frank Watanabe - President and CEO Todd Edwards - Chief Commercial Officer Patrick...
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.73 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports